DSGN — Design Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $263.97m
- $18.50m
- 48
- 33
- 84
- 55
Annual income statement for Design Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.226 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 8.56 | 35.8 | 67.6 | 78.2 | 62.4 |
| Operating Profit | -8.33 | -35.8 | -67.6 | -78.2 | -62.4 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -8.28 | -35.5 | -63.3 | -66.9 | -49.6 |
| Net Income After Taxes | -8.28 | -35.5 | -63.3 | -66.9 | -49.6 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -8.28 | -35.5 | -63.3 | -66.9 | -49.6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -8.28 | -35.5 | -63.3 | -66.9 | -49.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.154 | -0.774 | -1.14 | -1.19 | -0.876 |
| Dividends per Share |